Investing Profile
Frank Torti
Investor
Vant Chair at Roivant Sciences
United States
Your Intro Paths to Frank Torti
Signal uses Gmail to reveal intro paths. Email content is never read.
Sign in with Google →Networks Frank is a member of
Harvard Business School Network
423 CONNECTIONS
New Enterprise Associates (NEA) Network
42 CONNECTIONS
New Enterprise Associates Network
16 CONNECTIONS
Find Frank Torti on
cbCurrent Investing Position
Investor
Investment Range
$10K - $50K
Sweet Spot
$25K
Investments On Record
13
Frank Torti is on these Sector & Stage Rankings
Frank Torti's Investments On Record (6)
| Company | StageDateRound Size | Total Raised |
|---|---|---|
Annexon Biosciences | Series CJul 2020$100M  Series CDec 2018$75M Series BJun 2016$44M  | $220M |
Galera Therapeutics | Series CSep 2018$70M Series BFeb 2016$5M Series BOct 2015$37M Series AAug 2014$5M Series ADec 2012$11M | $130M |
Xoc Pharmaceuticals | Series AFeb 2018$30M | $30M |
OrphoMed | Series AMay 2017$39M | $39M |
Tarveda Therapeutics | Series CJan 2016$38M | $110M |
CITIC Pharmaceutical | Series DDec 2009$1M Series CApr 2008$22M | $23M |
Frank Torti's Experience
CEO and Chairman Telavant2022 - Present
Vant Chair Roivant Sciences2018 - Present
Partner New Enterprise Associates2007 - 2018
Partner New Enterprise Associates (NEA)2007 - 2018
Frank Torti's Education
Harvard Business School MBA
University of North Carolina at Chapel Hill School of Medicine MD
Founders who looked at Frank Torti's profile also looked at these Investors